Researchers at Toulouse University Hospital have secured nearly €600,000 in funding from the French National Cancer Institute to study minimal residual disease in lung cancer. Led by Professor Julien Mazières, the three-year project uses liquid biopsies to detect dormant tumor cells before clinical relapse occurs in patients treated with targeted therapies.
Lung cancer remains a formidable global health crisis, standing as the leading cause of cancer-related mortality worldwide and the primary driver of cancer deaths in France among men, while continuing an upward trajectory among women. Although targeted therapies have transformed modern oncology, long-term survival rates remain challenged by acquired drug resistance. A team at the Toulouse University Hospital (CHU de Toulouse) and the Cancer Research Center of Toulouse (CRCT/Inserm) is now stepping up efforts to outmaneuver these cellular escape mechanisms.
Professor Julien Mazières, an Inserm researcher and pneumo-oncologist at CHU de Toulouse, has been awarded a €600,000 grant as part of the national PRT-K 2026 funding call launched by the French National Cancer Institute (INCa) alongside the Directorate-General for Healthcare (DGOS). The funding directly supports a three-year investigational initiative aimed at intercepting lung cancer recurrence before standard imaging technologies can detect a returning tumor.
Tracking Minimal Residual Disease via Liquid Biopsies
The core clinical challenge in modern precision oncology is the persistence of micro-scale tumor populations that survive initial rounds of targeted medication. In non-small cell lung cancer (NSCLC) driven by specific genetic alterations—most notably mutations in the epidermal growth factor receptor (EGFR) gene—treatments like osimertinib often achieve profound, durable responses. Patients frequently experience disease control lasting months or years. Yet, a tiny fraction of cancer cells inevitably withstands the pharmacological assault.
These surviving cells constitute what oncologists define as minimal residual disease (MRD). Invisible to standard computed tomography (CT) scans, these dormant cells adapt, mutate, and eventually drive clinical resistance and relapse. According to Professor Mazières, secondary lines of treatment deployed after a overt relapse rarely match the efficacy of initial therapies. Consequently, the Toulouse team’s strategy is to intervene preemptively.
To capture these elusive cells without resorting to invasive repeat tissue sampling of the lung, the research team will utilize liquid biopsies. By analyzing circulating tumor cells extracted from routine blood draws, investigators aim to harvest critical genomic data while the patient remains clinically stable. This approach allows clinicians to map the early evolutionary trajectories of drug resistance long before a radiological scan flags a recurrence.
Integration with the COALA Network and Patient Cohort
The newly funded study will prospectively enroll 50 patients diagnosed with EGFR-mutated lung adenocarcinoma who are undergoing treatment with osimertinib. By closely monitoring this cohort through serial blood samples, investigators hope to chart the precise biological mechanisms of tumor escape. This granular molecular data will pave the way for bespoke secondary interventions, which may incorporate alternative targeted agents, antibody-drug conjugates, or CAR-T-cells.
The initiative is structurally anchored within COALA, a national clinical excellence network dedicated to accelerating translational research in lung cancer. By uniting clinical oncologists, laboratory researchers, and patient advocates under a shared framework, the COALA network facilitates rapid data sharing and scales promising local innovations into broader therapeutic paradigms. This collaborative architecture ensures that discoveries made in Toulouse can efficiently inform national clinical guidelines and benefit a wider demographic of patients.
In Plain English: The Clinical Takeaway
- Minimal Residual Disease (MRD): Refers to a tiny, undetectable pool of cancer cells that survive initial successful treatment, hiding in the body and eventually causing the cancer to return.
- Liquid Biopsy: A simple blood test that screens for floating pieces of tumor DNA or stray cancer cells, sparing patients from invasive surgical tissue biopsies.
- Targeted Therapy Resistance: The biological process where cancer cells mutate or adapt to drugs like osimertinib, rendering the medication ineffective over time.
Comparative Landscape of Lung Cancer Therapeutic Evolution
| Treatment Era | Primary Mechanism | Main Limitation |
|---|---|---|
| Conventional Chemotherapy | Induces systemic cytotoxicity by disrupting rapidly dividing cells. | Acts blindly, frequently damaging healthy tissue and yielding lower response durability. |
| Targeted Therapy | Inhibits specific oncogenic drivers (e.g., EGFR, ALK, ROS1 mutations). | High initial efficacy, but inevitably challenged by acquired resistance from surviving dormant cells. |
| Preemptive MRD Interception (New Toulouse Trial) | Tracks circulating tumor biomarkers via liquid biopsy to deploy secondary therapies early. | Currently restricted to a specialized 50-patient cohort pending broader network validation. |
Contraindications & When to Consult a Doctor
Liquid biopsies and exploratory monitoring protocols described in this research are investigational frameworks governed by active clinical trials; they do not replace standard surveillance imaging or established oncology care.
Future Outlook in Precision Oncology
Securing nearly €600,000 in dedicated public funding underscores the growing emphasis on proactive oncology over reactive relapse management. By catching resistance mechanisms in their infancy, researchers at Toulouse University Hospital and the CRCT are working to extend disease-free survival intervals and fundamentally alter the natural history of advanced lung cancer. As data from the 50-patient cohort matures and integrates with the national COALA infrastructure, the medical community moves one step closer to transforming lung cancer from a fatal diagnosis into a persistently manageable chronic condition.
References
- Institut National du Cancer (INCa). National Research Calls and Funding Allocations (PRT-K 2026).
- CHU de Toulouse. Clinical Research and Innovation Department Press Releases on COALA Network Initiatives.
Disclaimer: This article is for informational purposes only and does not constitute formal medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare professional for individual medical concerns.
